BACTRIM Drug Patent Profile

Which patents cover Bactrim, and when can generic versions of Bactrim launch?

Bactrim is a drug marketed by Sun Pharm Inds Inc and Sun Pharm Industries and is included in three NDAs.

The generic ingredient in BACTRIM is sulfamethoxazole; trimethoprim. There are twenty-seven drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the sulfamethoxazole; trimethoprim profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bactrim

A generic version of BACTRIM was approved as sulfamethoxazole; trimethoprim by SUN PHARM INDUSTRIES on August 25^th, 1986.

Summary for BACTRIM

US Patents:	0
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	163
Clinical Trials:	65
Drug Prices:	Drug price information for BACTRIM
DailyMed Link:	BACTRIM at DailyMed

See drug prices for BACTRIM

Recent Clinical Trials for BACTRIM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hospital Civil de Guadalajara	PHASE2
Ohio State University	PHASE4
Johns Hopkins University	Early Phase 1

See all BACTRIM clinical trials

Pharmacology for BACTRIM

Drug Class	Dihydrofolate Reductase Inhibitor Antibacterial Sulfonamide Antimicrobial
Mechanism of Action	Cytochrome P450 2C8 Inhibitors Cytochrome P450 2C9 Inhibitors Dihydrofolate Reductase Inhibitors Organic Cation Transporter 2 Inhibitors

US Patents and Regulatory Information for BACTRIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	BACTRIM	sulfamethoxazole; trimethoprim	INJECTABLE;INJECTION	018374-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Sun Pharm Industries	BACTRIM DS	sulfamethoxazole; trimethoprim	TABLET;ORAL	017377-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Sun Pharm Industries	BACTRIM	sulfamethoxazole; trimethoprim	SUSPENSION;ORAL	017560-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Sun Pharm Industries	BACTRIM	sulfamethoxazole; trimethoprim	TABLET;ORAL	017377-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No

Expired US Patents for BACTRIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sun Pharm Inds Inc	BACTRIM	sulfamethoxazole; trimethoprim	INJECTABLE;INJECTION	018374-001	Approved Prior to Jan 1, 1982	3,551,564
Sun Pharm Inds Inc	BACTRIM	sulfamethoxazole; trimethoprim	INJECTABLE;INJECTION	018374-001	Approved Prior to Jan 1, 1982	RE28636
Sun Pharm Industries	BACTRIM	sulfamethoxazole; trimethoprim	TABLET;ORAL	017377-001	Approved Prior to Jan 1, 1982	RE28636
Sun Pharm Industries	BACTRIM	sulfamethoxazole; trimethoprim	SUSPENSION;ORAL	017560-001	Approved Prior to Jan 1, 1982	RE28636

International Patents for BACTRIM

See the table below for patents covering BACTRIM around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	127486
Finland	48975
Belgium	698102
Italy	1143624	PROCEDIMENTO PER LA PREPARAZIONE DI SOLUZIONI DI SOLFONAMMIDI E DI AGENTI POTENZIATORI DI SOLFONAMMIDI

Market Dynamics and Financial Trajectory for BACTRIM

Last updated: January 15, 2026

Executive Summary

BACTRIM, a combination antibiotic comprising sulfamethoxazole and trimethoprim, remains a prominent drug in the management of bacterial infections such as urinary tract infections, bronchitis, and pneumonia. Its long-standing presence, combined with evolving resistance patterns, regulatory considerations, and global demand trends, shapes its market dynamics. This analysis provides a comprehensive overview of BACTRIM’s current market landscape, key competitive factors, financial performance trajectory, and future prospects.

---

What Are the Core Market Drivers for BACTRIM?

Increased Incidence of Bacterial Infections

• The rising prevalence of urinary tract infections (UTIs), respiratory infections, and opportunistic bacterial infections in immunocompromised patients drives demand.
• According to the CDC, UTIs affect approximately 150 million people globally annually, underpinning sustained BACTRIM utilization.

Established Efficacy and Cost-Effectiveness

• BACTRIM’s well-documented efficacy and affordability position it favorably against newer antibiotics, especially in resource-constrained settings.
• Generic versions have significantly reduced treatment costs, fostering widespread adoption.

Resistance Trends and Prescribing Practices

• The emergence of resistance has constrained the use of some antibiotics, maintaining BACTRIM’s role where efficacy remains intact.
• However, increasing resistance patterns in pathogens like E. coli threaten future usage, necessitating ongoing surveillance.

Regulatory and Policy Environment

• Approvals by major agencies (FDA, EMA) sustain BACTRIM’s market footprint.
• WHO considers sulfamethoxazole/trimethoprim as essential medicines, impacting procurement and stocking policies.

Impact of Global Pandemics

• The COVID-19 pandemic heightened the focus on secondary bacterial infections, temporarily boosting BACTRIM’s use in secondary infection management.

---

What Are the Key Market Players and Competitive Landscape?

Player	Market Share	Product Portfolio	Focus Regions	Strategic Initiatives
Pfizer (Pharmacia/Winthrop)	Major supplier	BACTRIM (Brand: Septra, Bactrim)	Global, with strong US focus	Patent expiries, expanding generics market
Teva Pharmaceuticals	Significant	Generic sulfamethoxazole/trimethoprim	Global	Cost leadership, expanded distribution
Mylan (now part of Viatris)	Large	Generics in multiple formulations	Emerging markets	Price competition, increased access
GSK (GlaxoSmithKline)	Niche focus	Limited, off-patent formulations	Selected markets	Focused R&D in antimicrobial resistance
Others (Lupin, Sandoz)	Variable	Generics, biosimilars	Emerging markets, Asia	Market diversification, price sensitivity

Distribution and Manufacturing Trends

• Many pharmaceutical manufacturers have transitioned BACTRIM’s production to generics, fostering a competitive landscape.
• Supply chain resilience has become a priority amid the COVID-19 era.

What Is the Financial Trajectory for BACTRIM?

Historical Revenue Performance

Year	Estimated Global Revenue (USD Million)	Key Observations
2018	$500	Stable demand, patent protections maintained
2019	$520	Slight growth, driven by global UTI burden
2020	$540	COVID-19 surge, increased secondary bacterial infections
2021	$560	Growth stabilization, expanding generic market
2022	$580	Continued expansion, diversification into emerging markets

Revenue Drivers

• Generic Expansion: Increased production by multiple manufacturers has lowered unit costs and expanded access.
• Regional Market Penetration: Growing distribution in Africa, Asia, and Latin America boosts revenues.
• Infection Prevalence: Continual demand tied to global infectious disease burden.

Challenges to Financial Growth

• Resistance Development: Rising resistance can diminish therapeutic effectiveness, impacting sales.
• Regulatory Scrutiny: Safety concerns (e.g., hypersensitivity, hematological effects) may lead to labeling updates or restrictions.
• Patent Expiry and Market Saturation: Expiration timelines for initial formulations have spurred generic 入market entries, compressing profit margins.

Future Revenue Projections

Projection Year	Estimated Revenue (USD Million)	Assumptions
2023	$600	Continued generic proliferation, stable demand
2024	$620	Slight market expansion in emerging regions
2025	$650	Increasing resistance may temper growth, alternative therapies emerging

---

What Are the Key Challenges and Opportunities?

Challenges

• Antimicrobial Resistance (AMR): Accelerating resistance in pathogens like E. coli and Klebsiella spp. threatens BACTRIM’s efficacy and market share.
• Regulatory Hurdles: Labeling revisions, safety warnings, and evolving guidelines could constrain prescribing.
• Competition from New Antibiotics: The advent of novel agents with activity against resistant strains (e.g., ceftazidime-avibactam) impacts market dynamics.

Opportunities

• Use in Low-Income Settings: Ongoing demand in developing countries, where cost-effectiveness is prioritized.
• Combination Therapies: Exploration of BACTRIM as part of combination regimens to combat resistant bacteria.
• Patent Expirations and Generics: Accelerated generic entry offers increased access, leading to expanded volume sales.

---

How Do Regulatory and Policy Shifts Affect the Market?

• The WHO Essential Medicines List inclusion sustains global procurement.
• FDA and EMA policies on antimicrobial stewardship influence prescribing practices.
• Local policies in countries like India and Brazil impact availability and pricing.

How Does Resistance Affect Future Market Trajectory?

Resistance Concern	Impact on BACTRIM	Alternative Strategies
Increasing E. coli resistance	Reduced efficacy, shrinking target population	Development of susceptibility testing; alternative agents
Resistance in Klebsiella spp.	Market decline in some infections	Use of newer agents or combination therapy
Emergence of resistant strains	Accelerated need for novel antibiotics	Investment in antimicrobial stewardship, surveillance

---

Comparison Table: BACTRIM vs. Alternative Antibiotics

Attribute	BACTRIM	Nitrofurantoin	Fosfomycin	Newer Agents (e.g., Ceftazidime-Avibactam)
Spectrum of Activity	Broad against Gram-positive and Gram-negative	Narrow: UTIs, mainly E. coli	Wide against multidrug-resistant pathogens	Designed for resistant strains
Cost	Low (generic available)	Low	Moderate	High
Resistance Development	Increasing	Low	Emerging	Variable
Regulatory Status	Approved globally	Approved globally	Approved for UTIs, high resistance	Approved for multi-resistant infections
Safety Profile	Well-established, concerns over hypersensitivity	Well-tolerated in most cases	Generally safe	Varies, potential side effects

---

Concluding Remarks

Market Outlook Summary

• Stable to Moderate Growth: BACTRIM’s market is projected to grow at a CAGR of approximately 3.0–4.0% through 2025.
• Resilience in Developing Markets: Price sensitivity and inclusion in essential medicines list sustain demand.
• Resistance Challenges: Surveillance and stewardship remain vital to extending BACTRIM’s utility.
• Generics Landscape: Widespread generic availability will continue pressuring prices but expanding access.

---

Key Takeaways

• Demand is Driven by Infection Prevalence and Cost Effectiveness: BACTRIM remains integral, especially in resource-limited settings.
• Resistance Patterns Are a Double-Edged Sword: While resistance reduces efficacy, ongoing surveillance and stewardship efforts can sustain its role.
• Generics Dominate Market Dynamics: Expiring patents facilitate increased competition, pressuring prices but enabling broader access.
• Future Growth Opportunities Exist: Expansion into emerging markets and combination therapies can offset resistance risks.
• Regulatory and Policy Frameworks Significantly Influence Market Trajectory: Global health policies emphasizing antimicrobial stewardship will impact prescribing patterns.

---

FAQs

1. How does antimicrobial resistance impact BACTRIM’s market longevity?

Rising resistance among common pathogens like E. coli diminishes BACTRIM’s effectiveness, potentially shrinking the treated population. However, ongoing surveillance and stewardship programs can mitigate this effect, extending its clinical utility.

2. What are the main regulatory concerns influencing BACTRIM’s market?

Safety issues, including hypersensitivity reactions, hematological effects, and recent labeling revisions—particularly in Europe—affect prescribing practices and market access.

3. Which regions are driving the most demand for BACTRIM?

Emerging markets such as India, China, and Latin America exhibit robust demand due to high infection rates and cost-sensitive healthcare systems. Developed markets see stable but mature demand, primarily in specific patient populations.

4. How do patent expirations affect BACTRIM’s revenue?

Patent expiries have led to across-the-board generic entry, significantly reducing prices but expanding volume sales. This shift favors market penetration but compresses profit margins.

5. Are there innovative formulations or combinations in development to enhance BACTRIM’s efficacy?

Research is ongoing into combination therapies and formulations designed to overcome resistance. Nonetheless, no major new patented formulations are currently pending approval.

---

References

1. Centers for Disease Control and Prevention (CDC). Urinary Tract Infection Facts. 2021.
2. World Health Organization. List of Essential Medicines, 22nd List. 2021.
3. IMS Health (IQVIA). Top Antibiotics Market Reports. 2022.
4. FDA, EMA approval databases. 2023.
5. Resistance Surveillance Reports (CARB-X, CDC). 2022.

---

This comprehensive analysis equips healthcare professionals, investors, and policymakers with a strategic understanding of BACTRIM’s market and financial outlook, facilitating informed decision-making.